NIH Granted Gene Therapy Patent
WASHINGTON--The U.S. Patent and Trademark Office has awarded a broad patent on gene therapy to the National Institutes of Health. Six years after filing the application, NIH and its licensee, Genetic Therapy, Inc. of Gaithersburg, Maryland, can now use the patent for ex vivo human gene therapy.
WASHINGTON--The U.S. Patent and Trademark Office has awarded abroad patent on gene therapy to the National Institutes of Health.Six years after filing the application, NIH and its licensee,Genetic Therapy, Inc. of Gaithersburg, Maryland, can now use thepatent for ex vivo human gene therapy.
In this technique, human cells are manipulated in the laboratoryto express potentially therapeutic genes, which are then introducedinto a patient to treat disease. Coinventors of the techniqueare Michael Blaese, MD, and Stephen A. Rosenberg, MD, PhD, bothNIH scientists, and W. French Anderson, MD, a former NIH researchernow at the University of Southern California Norris Cancer Center.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Elevating the Quality of Cancer Care via Cross-Department Collaboration
Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.
Artificial Intelligence in Cancer Care: Addressing Challenges and Health Equity
Artificial intelligence may mitigate overdiagnosis and unnecessary treatments in cancer cancer care by integrating with precision medicine.
